pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,239 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1565Hematology1354Pulmonology1264Vaccines
  • Aurora Therapeutics drops PKU program and trims staff
    Aurora Therapeutics, a gene-editing startup founded by Jennifer Doudna, announced it is abandoning its lead phenylketonuria (PKU) program. The decision follows growing competition in the PKU field…
    BioSpace · 1mo agoLayoffsNegative↗ source
  • Call to unify MD and DO medical education pathways
    Physicians Abigail MacKenzie and Vijay Rajput argue that keeping medical education split between allopathic (MD) and osteopathic (DO) tracks is an outdated practice that adds no value to patient ca…
    STAT · 1mo agoPositive↗ source
← prev
page 32 of 90
next →
73
fda recalls72
fda medwatch62
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain503
Endocrinology & Metabolism495
Infectious Disease457
  • Schrödinger CEO Ramy Farid rethinks role of AI in drug discovery
    In a recent STAT AI Prognosis newsletter, Schrödinger chief executive Ramy Farid discussed how his perspective on artificial intelligence is evolving. He reflected on recent conversations about AI…
    STAT · 1mo agoNeutral↗ source
  • Opinion: Films on assisted dying often ignore socioeconomic factors as New York law takes effect
    The piece, authored by Anna Magdalena Elsner and Vanessa Rampton, notes that New York's Medical Aid in Dying Act will become law on Aug 5, 2026, marking a major policy shift for terminally ill pati…
    STAT · 1mo agoNeutral↗ source
  • Novo Nordisk shares slide 6% after Wegovy pill sales miss despite earnings beat
    Novo Nordisk reported second‑quarter results that beat both revenue and profit forecasts, posting a profit of $5.15 billion. The company’s oral Wegovy obesity pill generated $496 million in sales,…
    BioSpace · 1mo agoEarningsNegative↗ source
  • Vertex posts strong Q2 earnings, but upcoming Sionna cystic fibrosis data casts a shadow
    Vertex reported Q2 revenue from its cystic fibrosis portfolio exceeding $3.2 billion, beating estimates and prompting an upward revision of full‑year revenue guidance to $13.1‑$13.2 billion. Analy…
    BioPharma Dive · 1mo agoEarningsNeutral↗ source
  • BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demand
    BioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…
    BioSpace · 1mo agoEarningsNegative↗ source
  • Pathos AI signs two cancer deals, including $2 bn contract with China's Alphamab and partnership with AstraZeneca
    Pathos AI announced two new collaborations to expand its oncology pipeline, one with AstraZeneca and another with a subsidiary of China's Alphamab Oncology. The deal with Jiangsu Alphamab Biopharm…
    BioSpace · 1mo agoDealPositive↗ source
  • Ebola outbreak in eastern Congo kills over 1,700 as cases surge past 3,800
    The latest government report shows that the Ebola outbreak in eastern Congo has resulted in more than 1,700 deaths and a total of 3,802 recorded cases. Health officials say that about 60-70% of ne…
    STAT · 1mo agoNegative↗ source
  • Pfizer CEO says $7 billion cash ready for bolt‑on acquisitions and dividend will stay intact
    During its second‑quarter earnings call, analysts asked Pfizer if the company would increase M&A spending as rivals rush to buy biotech assets. CEO Albert Bourla replied that Pfizer currently has…
    BioSpace · 1mo agoDealPositive↗ source
  • Gilead wins legal battle over HIV drug as Eli Lilly opens early access program for obesity therapy retatrutide
    Gilead Sciences secured a court victory concerning one of its HIV medicines, according to the brief report. The ruling resolves a legal dispute that had been pending, allowing the company to contin…
    STAT · 1mo agoRegulatoryPositive↗ source
  • Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativa
    Merck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…
    BioSpace · 1mo agoNegative readoutNeutral↗ source
  • J&J pharma chief Jennifer Taubert to retire; Krystal Biotech shares plunge after gene therapy revenue shortfall
    Johnson & Johnson announced that Jennifer Taubert will step down as head of its pharmaceutical division after a 21‑year tenure. During her time she oversaw commercial strategy, dealmaking and the…
    BioPharma Dive · 1mo agoNegative↗ source
  • UK regulator debates whether AI scribes count as medical devices
    UK regulators are examining whether AI-driven clinical documentation tools, often called AI scribes, should be classified as medical devices under current law. The proposal has generated debate am…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Pfizer adds $2.5 billion to restructuring, targeting $6 billion savings by 2029
    Pfizer announced an additional $2.5 billion in cost reductions as part of its ongoing restructuring program. The new cuts focus on technology and simplification across commercial, R&D and manufact…
    BioSpace · 1mo agoNegative↗ source
  • Analysis questions expanded orphan drug exemptions under recent legislation
    Ed Silverman, a Pharmalot columnist, examined a provision in the One Big Beautiful Bill Act that keeps certain orphan drugs out of Medicare price negotiations. The Inflation Reduction Act, which b…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Kennedy and Oz dismiss Medicaid cut claims, but state officials warn new rules could strip coverage
    Health secretary Robert F. Kennedy Jr. and former Vice President Dan Oz asserted that the administration is not cutting Medicaid, calling the idea a myth during a farm visit in Michigan. State Med…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Pfizer expands cost-cutting program, targeting $1 billion in new savings through 2029
    Pfizer announced it is expanding a cost-cutting initiative first launched in 2023 to further reduce expenses. The new measures are projected to generate about $1 billion in additional savings by 2…
    BioPharma Dive · 1mo agoNeutral↗ source
  • As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
    While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
    BioSpace · 1mo agoDealNeutral↗ source
  • Eli Lilly expands early-access program for experimental obesity drug retatrutide
    Eli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity. The company said the program will let additional patients apply for the…
    STAT · 1mo agoRegulatoryPositive↗ source
  • Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves ahead
    Aurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…
    STAT · 1mo agoLayoffsNegative↗ source
  • Early Alert: Intraosseous Needle Set Issue from Becton Dickinson
    BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
    fda medwatch · 1mo agoRegulatoryNeutral↗ source
  • Lilly expands access to its experimental obesity therapy while Jazz pulls Zepzelca's second-line lung cancer use
    Lilly announced it will broaden the expanded‑access program for its obesity drug that has not yet received regulatory approval, allowing more patients to receive the treatment under a compassionate…
    raps · 1mo agoRegulatoryNeutral↗ source
  • FDA invites stakeholder input to shape a new Quantitative Medicine Innovation Network
    The FDA announced it is looking for feedback from a broad range of stakeholders to help design a Quantitative Medicine Innovation Network (QMIN). The proposed QMIN would be a cross-sector platform…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Lisata Therapeutics cuts 72% of staff after merger with Kuva falls through and files lawsuit
    Lisata Therapeutics announced it is cutting about 72% of its full‑time workforce after a planned merger with Kuva Labs collapsed. The company had 21 full‑time employees at the end of 2025, so roug…
    BioSpace · 1mo agoLayoffsNegative↗ source